SCHEMBL6570677

SCHEMBL6570677

COc1ccc2c(c1)C[C@@H](C)[C@H]1[C@@H]3[C@H](C)C=C(O[Si](C)(C)C)[C@@]3(C)CC[C@H]21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.43
LMNA P02545 4/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
HSD17B10 Q99714 1/20 0.38
ESR1 P03372 4/20 0.37
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 1/20 0.36
HIF1A Q16665 1/20 0.36
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
CNR1 P21554 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
STS P08842 2/20 0.35
CHRNB2 P17787 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4370456 0.82 LMNA (0.42) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6462744 0.79 LMNA (0.44) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6462748 0.79 LMNA (0.52) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6569575 0.79 LMNA (0.52) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL3877022 0.77 HSD17B1 (0.39) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6465736 0.76 LMNA (0.48) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6465738 0.76 LMNA (0.48) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6569630 0.75 HRH3 (0.39) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6569627 0.75 HRH3 (0.39) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL6466520 0.74 LMNA (0.51) HSD17B1LMNAMAPTRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040059140-A1 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile VAN DER LOUW JAPP (NL) 2004-03-25 US disclosed
EP-1343804-A1 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE Akzo Nobel N.V. (NL) 2003-09-17 EP disclosed
WO-2002048169-A1 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE AKZO NOBEL N.V. (NL) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059140-A1 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile HSD17B11, CYP17A1, SHBG HSD17B1 8/4885LMNA 2074/4885MAPT 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.